AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15058892 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic intensity program (n = 34)
Number of subjects: 66
Study 15058892 — intervention group
Group type: COMPARATOR
Intervention: Control intensity program (n = 32)
Number of subjects: 66
Study 12791001 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loperamide (12 mg daily, 4 mg t.d.s.)
Number of subjects: 10
Study 12791001 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository loperamide (12 mg daily, 6 mg b.d.)
Number of subjects: 10
Study 12791001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12791001 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loperamide
Number of subjects: 10
Study 12791001 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository loperamide
Number of subjects: 10
Study 11273109 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/captopril
Number of subjects: 25
Study 11273109 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (digitalis and diuretics)
Number of subjects: 25
Study 8294092 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics alone
Number of subjects: 21
Study 2646188 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil 60 mg (morning and evening)
Number of subjects: 168
Study 2646188 — intervention group
Group type: COMPARATOR
Intervention: nifedipine retard 20 mg (morning and evening)
Number of subjects: 168
Study 2646188 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil
Number of subjects: 168
Study 2646188 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 168
Study 31621258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-acupuncture at Neiguan (PC 6) and Zusanli (ST 36), once a day for 5 days
Number of subjects: 50
Study 31621258 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 50
Study 28356097 — intervention group
Group type: EXPERIMENTAL
Intervention: Static goals
Number of subjects: 96
Study 28356097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive goals
Number of subjects: 96
Study 28356097 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate rewards
Number of subjects: 96
Study 28356097 — intervention group
Group type: COMPARATOR
Intervention: Delayed rewards
Number of subjects: 96
Study 26170035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management (ICMM)
Number of subjects: 521
Study 26170035 — intervention group
Group type: COMPARATOR
Intervention: Linkage model (LM)
Number of subjects: 521
Study 26170035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case management)
Number of subjects: 521
Study 24074357 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 80
Study 24074357 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 80
Study 24074357 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 80
Study 24074357 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 80
Study 24074357 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 80
Study 21235465 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of diclofenac sodium (75 mg/mL)
Number of subjects: 14
Study 21235465 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of diclofenac sodium (75 mg/3 mL)
Number of subjects: 14
Study 18480187 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress task (8 minutes)
Number of subjects: 118
Study 18480187 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress task (similar to experiment 1)
Number of subjects: 118
Study 18480187 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress task
Number of subjects: 118
Study 16930104 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS)
Number of subjects: 65
Study 16930104 — intervention group
Group type: COMPARATOR
Intervention: Heparinised saline (HS)
Number of subjects: 65
Study 15966561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early gonadotropin-releasing hormone (GnRH) agonist cessation protocol with leuprorelin 0.5 mg for 10-14 days followed by high doses of gonadotropins.
Number of subjects: 0
Study 15966561 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose flare protocol utilizing oral contraceptive priming followed by diluted doses of leuprorelin 50 microg twice daily and high doses of gonadotropins.
Number of subjects: 0
Study 15966561 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ultrasound measurements predicting low response to IVF therapy.
Number of subjects: 0
Study 15966561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stromal blood flow measurement.
Number of subjects: 0
Study 10889565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (VIAGRA(R))
Number of subjects: 178
Study 9155717 — intervention group
Group type: EXPERIMENTAL
Intervention: CFTR cDNA-liposome complexes delivered by topical application
Number of subjects: 12
Study 9155717 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (liposome alone)
Number of subjects: 12
Study 9155717 — intervention group
Group type: EXPERIMENTAL
Intervention: CF subjects (combined treatment and control)
Number of subjects: 12
Study 9155717 — intervention group
Group type: COMPARATOR
Intervention: Non-CF subjects (surgically resected tissues)
Number of subjects: 12
Study 8174966 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 30
Study 8174966 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 30
Study 8174966 — intervention group
Group type: COMPARATOR
Intervention: Control (Patients without autonomic neuropathy)
Number of subjects: 30
Study 3492358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g every 12 hours for a mean duration of 11 days
Number of subjects: 42
Study 3492358 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole 1 double-strength tablet every 12 hours for a mean duration of 13 days
Number of subjects: 42
Study 29407501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary miniplates-based skeletal anchorage
Number of subjects: 28
Study 29407501 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 28
Study 27644672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (500 mg capsules, 2 times a day for 10 days)
Number of subjects: 65
Study 27644672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile (500 mg capsules, 2 times a day for 10 days)
Number of subjects: 65
Study 27644672 — intervention group
Group type: COMPARATOR
Intervention: Control (routine antiemetic regimen consisting of DMA capsules)
Number of subjects: 65
Study 25399007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (200 mg before surgery, then 100 mg daily for up to 30 days after surgery)
Number of subjects: 6905
Study 25399007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg before surgery, then transdermal patch providing 0.2 mg/d for 72 hours after surgery)
Number of subjects: 6905
Study 25399007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (presence of major bleeding)
Number of subjects: 6905
Study 25399007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (presence of clinically important hypotension)
Number of subjects: 6905
Study 22858211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early switch to duloxetine 60-120 mg/day
Number of subjects: 0
Study 22858211 — intervention group
Group type: COMPARATOR
Intervention: Conventional switch to escitalopram
Number of subjects: 0
Study 20394790 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically heated cigarette smoking system (EHCSS)
Number of subjects: 0
Study 20394790 — intervention group
Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 0
Study 20394790 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarette smoking (CC)
Number of subjects: 0
Study 18042650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 16
Study 18042650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15773825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-reversal Visual Evoked Potentials (VEPs) in migraineurs
Number of subjects: 181
Study 15773825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-reversal Visual Evoked Potentials (VEPs) in migraineurs without aura
Number of subjects: 181
Study 15773825 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 181
Study 15773825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-reversal Visual Evoked Potentials (VEPs)
Number of subjects: 181
Study 11799376 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics administered to mothers during pregnancy and lactation
Number of subjects: 62
Study 11799376 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to mothers during pregnancy and lactation
Number of subjects: 62
Study 10522061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan, tegafur, and cisplatin
Number of subjects: 0
Study 10522061 — intervention group
Group type: COMPARATOR
Intervention: Control group (tegafur and cisplatin)
Number of subjects: 0
Study 7553676 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 232
Study 7553676 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 232
Study 1950714 — intervention group
Group type: EXPERIMENTAL
Intervention: Study I
Number of subjects: 241
Study 1950714 — intervention group
Group type: EXPERIMENTAL
Intervention: Study II
Number of subjects: 241
Study 6248395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mg)
Number of subjects: 44
Study 6248395 — intervention group
Group type: COMPARATOR
Intervention: Orciprenaline (10 mg)
Number of subjects: 44
Study 31036105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (250 mg twice daily per oral, 10 mg/kg/day)
Number of subjects: 50
Study 31036105 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (200 mg daily per oral, 3.3 mg/kg/day)
Number of subjects: 50
Study 28005578 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 667
Study 28005578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 27113284 — intervention group
Group type: COMPARATOR
Intervention: Podiatric management and placebo phototherapy
Number of subjects: 3
Study 27113284 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric management with phototherapy on the ulcer(s)
Number of subjects: 3
Study 27113284 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric management with phototherapy applied to the regional lymphatic nodes and ulcer(s)
Number of subjects: 3
Study 23368510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide QD (10 µg weeks 1-2, then 20 µg)
Number of subjects: 148
Study 23368510 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg)
Number of subjects: 148
Study 23368510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 148
Study 23368510 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 148
Study 20309523 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily, self-administered injections at bedtime for 12 months)
Number of subjects: 20
Study 20309523 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (Control group)
Number of subjects: 20
Study 19441870 — intervention group
Group type: EXPERIMENTAL
Intervention: AliskirenHydrochlorothiazide (Aliskiren + HCTZ)
Number of subjects: 0
Study 19441870 — intervention group
Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 0
Study 16505130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 15 sessions
Number of subjects: 84
Study 16505130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SSRI) with a maximum dosage of 150 mg
Number of subjects: 84
Study 16505130 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study 14753333 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional incremental technique (Group A)
Number of subjects: 33
Study 14753333 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel curing devices (Group B and C)
Number of subjects: 33
Study 11801195 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release
Number of subjects: 0
Study 11801195 — intervention group
Group type: COMPARATOR
Intervention: Wrist splinting during the night for at least 6 weeks
Number of subjects: 0
Study 9344302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic phenytoin (Dilantin®) for prevention of posttraumatic seizures
Number of subjects: 63
Study 8392287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, ifosfamide, and cisplatin (MIP)
Number of subjects: 100
Study 8392287 — intervention group
Group type: COMPARATOR
Intervention: Vindesine, ifosfamide, and cisplatin (VIP)
Number of subjects: 100
Study 8392287 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MIP and VIP
Number of subjects: 100
Study 3639894 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital thermometers
Number of subjects: 0
Study 3639894 — intervention group
Group type: COMPARATOR
Intervention: Mercury thermometers
Number of subjects: 0
Study 30697968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (1 watt) in addition to scaling and root planing (SRP)
Number of subjects: 37
Study 30697968 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment in addition to scaling and root planing (SRP)
Number of subjects: 37
Study 29763976 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled bathing
Number of subjects: 35
Study 29763976 — intervention group
Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 35
Study 26986617 — intervention group
Group type: EXPERIMENTAL
Intervention: Open group (aware of the sensor)
Number of subjects: 170
Study 26986617 — intervention group
Group type: COMPARATOR
Intervention: Blind group (unaware of the sensor)
Number of subjects: 170
Study 26986617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (water filters)
Number of subjects: 170
Study 26986617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cookstoves)
Number of subjects: 170
Study 25258524 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=34)
Number of subjects: 65
Study 25258524 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 65
Study 25258524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 22803428 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen Injection (CDI)
Number of subjects: 120
Study 22803428 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 120
Study 20041998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low zinc status
Number of subjects: 0
Study 20041998 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation (proposed intervention)
Number of subjects: 0
Study 18692695 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloSCT)
Number of subjects: 0
Study 16092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure 'I say to myself: I can solve this task'
Number of subjects: 46
Study 16092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure 'I get worried and will have problems solving other tasks too'
Number of subjects: 46
Study 16092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Test performance and academic self-esteem
Number of subjects: 46
Study 16092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva cortisol levels
Number of subjects: 46
Study 16092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress measured with VAS
Number of subjects: 46
Study 16092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological reactions to demands
Number of subjects: 46
Study 12621778 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine and serum TGF‐beta 1 and IL‐6 levels in patients with type II diabetes mellitus
Number of subjects: 68
Study 12621778 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial TGF‐beta 1 levels exceeding normal values
Number of subjects: 68
Study 12621778 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine TGF‐beta 1 level
Number of subjects: 68
Study 12621778 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine and serum TGF‐beta 1 and IL‐6 levels
Number of subjects: 68
Study 12621778 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 68
Study 10342084 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 177
Study 10342084 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 177
Study 8961973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for 5 years (20 mg/day orally)
Number of subjects: 2937
Study 8961973 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen therapy for 2 years (20 mg/day orally)
Number of subjects: 2937
Study 1945605 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 0
Study 1945605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lederle WCV
Number of subjects: 0
Study 1945605 — intervention group
Group type: COMPARATOR
Intervention: Connaught WCV
Number of subjects: 0
Study 6284687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6284687 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17
Study 31092125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment addressing 2 or more factors
Number of subjects: 1000000
Study 31092125 — intervention group
Group type: COMPARATOR
Intervention: Single factor treatment
Number of subjects: 1000000
Study 26024828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose S‐ILE (1 g/kg/d)
Number of subjects: 36
Study 26024828 — intervention group
Group type: COMPARATOR
Intervention: Control dose S‐ILE (3 g/kg/d)
Number of subjects: 36
Study 28514547 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib therapy
Number of subjects: 296
Study 24867027 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 40
Study 24867027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23031478 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 (2.5 mg/kg)
Number of subjects: 90
Study 23031478 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 (25 mg/kg)
Number of subjects: 90
Study 23031478 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (250 mg/kg)
Number of subjects: 90
Study 19544759 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 824
Study 19544759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 824
Study 17900362 — intervention group
Group type: EXPERIMENTAL
Intervention: Task/context-focused approach
Number of subjects: 220
Study 17900362 — intervention group
Group type: COMPARATOR
Intervention: Child-focused remediation approach
Number of subjects: 220
Study 16060423 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory modeling plus standard swimming curriculum for the butterfly stroke
Number of subjects: 37
Study 16060423 — intervention group
Group type: COMPARATOR
Intervention: Standard swimming curriculum for the butterfly stroke
Number of subjects: 37
Study 12421064 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial pooling of velocity information with object rotation
Number of subjects: 0
Study 12421064 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial pooling of velocity information with object translation
Number of subjects: 0
Study 12421064 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of objects in the scene
Number of subjects: 0
Study 10357416 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history of cancer
Number of subjects: 24848
Study 10357416 — intervention group
Group type: COMPARATOR
Intervention: Family members of cases
Number of subjects: 24848
Study 10357416 — intervention group
Group type: COMPARATOR
Intervention: Family relation to cases or controls
Number of subjects: 24848
Study 7496681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose craniospinal irradiation (25 Gy) followed by a boost to the posterior fossa (total dose 55 Gy)
Number of subjects: 22
Study 2024540 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg)
Number of subjects: 1210
Study 2024540 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (0.5 mg)
Number of subjects: 1210
Study 6177262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 18
Study 6177262 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 18
Study 29451949 — intervention group
Group type: EXPERIMENTAL
Intervention: GSS6Fr (6 French Glidesheath Slender)
Number of subjects: 1836
Study 29451949 — intervention group
Group type: COMPARATOR
Intervention: GS5Fr (standard 5 Fr Glidesheath)
Number of subjects: 1836
Study 29451949 — intervention group
Group type: EXPERIMENTAL
Intervention: GSS6Fr
Number of subjects: 1836
Study 29451949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostasis time
Number of subjects: 1836
Study 27608819 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralaterally controlled functional electrical stimulation (CCFES)
Number of subjects: 80
Study 27608819 — intervention group
Group type: COMPARATOR
Intervention: Cyclic neuromuscular electrical stimulation (cNMES)
Number of subjects: 80
Study 24709765 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL)
Number of subjects: 644
Study 24709765 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of disorder and disease severity
Number of subjects: 644
Study 24709765 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 644
Study 22409153 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative 1550-nm fractional Er: glass laser
Number of subjects: 0
Study 22409153 — intervention group
Group type: COMPARATOR
Intervention: Ablative 2940-nm fractional Er: YAG laser
Number of subjects: 0